1. Home
  2. SNTI vs ATIF Comparison

SNTI vs ATIF Comparison

Compare SNTI & ATIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNTI
  • ATIF
  • Stock Information
  • Founded
  • SNTI 2016
  • ATIF 2015
  • Country
  • SNTI United States
  • ATIF United States
  • Employees
  • SNTI N/A
  • ATIF N/A
  • Industry
  • SNTI Biotechnology: Pharmaceutical Preparations
  • ATIF Professional Services
  • Sector
  • SNTI Health Care
  • ATIF Consumer Discretionary
  • Exchange
  • SNTI Nasdaq
  • ATIF Nasdaq
  • Market Cap
  • SNTI 14.1M
  • ATIF 9.8M
  • IPO Year
  • SNTI N/A
  • ATIF 2019
  • Fundamental
  • Price
  • SNTI $2.19
  • ATIF $1.22
  • Analyst Decision
  • SNTI
  • ATIF
  • Analyst Count
  • SNTI 0
  • ATIF 0
  • Target Price
  • SNTI N/A
  • ATIF N/A
  • AVG Volume (30 Days)
  • SNTI 24.1K
  • ATIF 198.5K
  • Earning Date
  • SNTI 11-11-2024
  • ATIF 11-11-2024
  • Dividend Yield
  • SNTI N/A
  • ATIF N/A
  • EPS Growth
  • SNTI N/A
  • ATIF N/A
  • EPS
  • SNTI N/A
  • ATIF N/A
  • Revenue
  • SNTI $338,000.00
  • ATIF $500,000.00
  • Revenue This Year
  • SNTI $254.47
  • ATIF N/A
  • Revenue Next Year
  • SNTI $169.66
  • ATIF N/A
  • P/E Ratio
  • SNTI N/A
  • ATIF N/A
  • Revenue Growth
  • SNTI N/A
  • ATIF N/A
  • 52 Week Low
  • SNTI $1.52
  • ATIF $0.58
  • 52 Week High
  • SNTI $8.48
  • ATIF $1.50
  • Technical
  • Relative Strength Index (RSI)
  • SNTI 39.08
  • ATIF 64.12
  • Support Level
  • SNTI $2.08
  • ATIF $0.80
  • Resistance Level
  • SNTI $2.56
  • ATIF $1.12
  • Average True Range (ATR)
  • SNTI 0.24
  • ATIF 0.19
  • MACD
  • SNTI -0.04
  • ATIF -0.00
  • Stochastic Oscillator
  • SNTI 10.57
  • ATIF 63.45

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About ATIF ATIF Holdings Limited

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: